Clinical trials: Lymphomas,
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab…
- Trial name
- NCT02611323
- Testing
- Obinutuzumab, Rituximab, Polatuzumab Vedotin
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Lymphoma
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors…
- Trial name
- NCT04306224
- Testing
- IMC-002
- Where
- 4 sites in United States, South Korea
- Volunteers
- 12 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Refractory B-Cell Lymphoma
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.
- Trial name
- NCT03824964
- Testing
- Anti-CD19/CD22 CAR NK Cells
- Volunteers
- 10 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Follicular Lymphoma
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
It is a non-interventional study with a duration of approximately 24 months per participant to investigate the therapeutic efficiency, safety and treatment regimens of Rituximab maintenance therapy in daily routine in…
- Trial name
- NCT02536664
- Testing
- Rituximab
- Where
- Germany
- Volunteers
- 505 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Phase I clinical study of multicenter, single-arm, open, non-randomized evaluation of recombinant humanized anti-CD52 monoclonal antibody in the NHL and T-PLL
- Trial name
- NCT05557903
- Testing
- Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's…
- Conditions
- Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00150462
- Testing
- Carfilzomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Amgen
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Lymphoma, Large B-Cell, Diffuse
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL.
- Trial name
- NCT04790903
- Testing
- Venetoclax, Polatuzumab Vedotin, Rituximab
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Trial name
- NCT02855359
- Testing
- denintuzumab mafodotin, rituximab, cyclophosphamide
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- Seagen Inc.
Moderate/Severe Atopic Dermatitis
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
- Trial name
- NCT01745159
- Testing
- tacrolimus
- Where
- 4 sites in China
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma China, Inc.
Ulcerative Colitis
An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
The purpose of this study is to describe the long-term safety risks in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi.
- Trial name
- OPAL (NCT02808780)
- Where
- 63 sites in United States, Austria and 7 more
- Volunteers
- 535 people
- Sponsor
- Janssen Biotech, Inc.
B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT04150497
- Testing
- UCART22, CLLS52
- Where
- 19 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Cellectis S.A.
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
Evaluate the safety and tolerability of multiple doses of MEDI-538 by continuous IV infusion for 4 or 8 weeks in adult patients with B-cell NHL not eligible for curative therapy.
- Trial name
- NCT00538096
- Testing
- MEDI-538
- Volunteers
- 18 people
- Sponsor
- MedImmune LLC
Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit.
- Conditions
- Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
- Trial name
- NCT07609862
- Testing
- Lacutoclax+Rocbrutinib
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Non-hodgkin Lymphoma
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
- Trial name
- NCT06005649
- Testing
- HY004
- Sponsor
- Juventas Cell Therapy Ltd.
Large B-cell Lymphoma
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.
- Trial name
- SOUNDTRACK-D2 (NCT07215585)
- Testing
- AZD0486, R-mini-CHOP
- Where
- 82 sites in Australia, Belgium and 10 more
- Volunteers
- 420 people
- Sponsor
- AstraZeneca
T-cell Lymphoma
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma..
- Trial name
- NCT03952078
- Testing
- CPI-818
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 151 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL)
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor…
- Trial name
- NCT06392763
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.